Sign in

ODTX on Nasdaq

Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is an American biological products company based in Boston, incorporated in Delaware.1 Its shares trade on Nasdaq under the symbol ODTX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerODTX on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address51 Sleeper Street, Boston, Ma 022102
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Odyssey Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Odyssey Therapeutics, Inc.

  • Odyssey Therapeutics, Inc. Boston, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Odyssey Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Jason Haas2026–now
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorCarl D. Gordon named Oct 14, 2021 to Dec 4, 202517
  • DirectorJill D. Carroll named Oct 14, 2021 to Dec 4, 202517
  • DirectorKsenija F. Pavletic named Dec 4, 202517
  • DirectorNan D. Li named Dec 4, 202517
  • DirectorNia F. Tatsis named Dec 4, 202517
  • DirectorPaulina D. Hill named Dec 4, 202517
  • Directorlan F. Smith named Dec 4, 202517
  • DirectorCharles M. Baum named Oct 27, 2022 to Aug 14, 202418
  • DirectorLorence M. Kim named Aug 14, 202418
  • DirectorChuck D Baum named Oct 14, 202119

Timeline

  1. Sep 9, 20268-K Regulation FD disclosure20
  2. Aug 4, 20268-K Results of operations21
  3. Jun 23, 20268-K Regulation FD disclosure22
  4. Jun 17, 20268-K Results of operations23
  5. May 11, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed24

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/202625

When it reported results

  1. Aug 4, 2026Reported quarterly or annual results21
  2. Jun 17, 2026Reported quarterly or annual results23

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

68 filings to the SEC since October 2021: 2 quarterly reports, 5 major events, 34 insider forms, 6 large holders, 5 private raises, 16 other. The latest 20:

  1. Sep 9, 20268-K EDGAR
  2. Aug 6, 202610-Q EDGAR
  3. Aug 4, 20268-K EDGAR
  4. Jun 23, 20268-K EDGAR
  5. Jun 17, 20268-K EDGAR
  6. Jun 17, 202610-Q EDGAR
  7. Jun 5, 2026SCHEDULE 13G EDGAR
  8. May 18, 2026SCHEDULE 13G EDGAR
  9. May 18, 2026SCHEDULE 13D EDGAR
  10. May 18, 2026SCHEDULE 13D EDGAR
  11. May 15, 2026SCHEDULE 13D EDGAR
  12. May 15, 2026SCHEDULE 13D EDGAR
  13. May 13, 20264 EDGAR
  14. May 12, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. May 12, 20263 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. May 11, 20264 EDGAR
  17. May 11, 20264 EDGAR
  18. May 11, 20264 EDGAR
  19. May 11, 20264 EDGAR
  20. May 11, 20264 EDGAR

The 68 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 7 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 11, 2026COULTER JAMES GBuy1,388,889$18.00$25.0MForm 4
May 11, 2026George Simeon10% ownerBuy555,555$18.00$10.0MForm 4
May 11, 2026George Simeon10% ownerSale1,780$18.00$32.0KForm 4
May 11, 2026Li Nan (LN)DirectorBuy1,111,111$18.00$20.0MForm 4
May 11, 2026Chu ShelleyDirectorBuy11,111$18.00$200.0KForm 4
May 8, 2026LEIDEN JEFFREY MDirectorBuy5,000$20.00$100.0KForm 4
May 8, 2026Haas JasonChief Financial OfficerBuy1,000$20.00$20.0KForm 4
May 8, 2026Dimension Capital II, L.P.DirectorBuy1,111,111$18.00$20.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 16, 2025Raised $214 million in a private offering of equity Form D: 55 investors so far Form D
  2. Oct 25, 2023Raised $117.2 million in a private offering of equity Form D: $121.1 million offered in all Form D
  3. May 13, 2022Raised $168 million in a private offering of equity Form D: $174.9 million offered in all Form D
  4. Aug 30, 2021Raised $91.6 million in a private offering of equity Form D: 63 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 58. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC5,179,262$96.9M0.0%New
SR One Capital Management, LP3,794,883$71.0M6.8%New
Tpg Gp A, LLC3,690,146$69.0M1.4%New
Lightspeed Management Company, L.l.c.3,608,443$67.5M2.8%New
Orbimed Advisors LLC3,001,198$56.2M1.1%New
Sanofi1,991,918$37.3M7.0%New
Deerfield Management Company, L.P.1,046,139$19.6M0.2%New
Sands Capital Alternatives, LLC875,000$16.4M2.7%New
Hhlr Advisors, Ltd.831,656$15.6M1.9%New
General Catalyst Group Management, LLC810,272$15.2M8.0%New
Affinity Asset Advisors, LLC766,346$14.3M0.7%New
Adage Capital Partners Gp, L.l.c.725,000$13.6M0.0%New
Vanguard Capital Management LLC720,440$13.5M0.0%New
Foresite Capital Management V, LLC713,105$13.3M3.7%New
Vivo Capital, LLC575,000$10.8M1.0%New
EcoR1 Capital, LLC555,555$10.4M0.5%New
Logos Global Management LP521,736$9.8M0.4%New
Marshall Wace, Llp492,697$9.2M0.0%New
Catalio Capital Management, LP457,839$8.6M1.6%New
Redmile Group, LLC425,000$8.0M0.5%New
Balyasny Asset Management L.P.393,862$7.4M0.0%New
Woodline Partners LP345,746$6.5M0.0%New
Franklin Resources Inc275,022$5.1M0.0%New
Boxer Capital Management, LLC275,000$5.1M0.4%New
BlackRock, Inc.240,679$4.5M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Odyssey Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROdyssey Therapeutics, Inc.1
  • CIK0001882782
  • Employer ID (EIN)86-33843821
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address51 Sleeper Street, Boston, MA 022101
  • Phone(212) 841-10001
  • Shares outstanding48,058,527 as of Aug 3, 202632
  • On EDGAR sinceOct 14, 20211
  • Filings68 in all: 3 (19), 4 (15), 8-K (5), D (4), DRS/A (4), SCHEDULE 13D (4), 10-Q (2), DRS (2)1
    All 19 form types

    S-1 (2), SCHEDULE 13G (2), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), EFFECT (1), RW (1), S-1/A (1), S-1MEF (1), S-8 (1)

  • Latest filingsQuarterly report (10-Q) Aug 6, 2026
    Latest 8-K (8-K) Sep 9, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32